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ABSTRACT
Elyse Jeannette Baum
Characterizing the Effects of Prostaglandin E2 on Tendon Mechanical Properties
(Under the direction of Paul Weinhold)
Tendinopathy is a common clinical problem, both athletically and occupationally. It
develops from repetitive mechanical loading of tendon; however the molecular
mechanisms are not well understood. It is thought that prostaglandin E2 (PGE2) and
matrix metalloproteinases (MMPs) play a role in the early stages of tendinopathy
development. This research utilizes a rat tail tendon fascicle explant model to
characterize the effects of PGE2 in statically loaded and unloaded tendon. These effects
were quantified through creep measurement during culture and tensile failure tests of the
tissue after culture. Both specific and nonspecific MMP inhibitors were used in the
system to better characterize the molecular mechanism of PGE2’s action in the tissue.
We found that MMP inhibitors and static loading prevents PGE2 from decreasing the
mechanical properties of the tissue.
iii
This work is dedicated to Jeffrey, Mom, Dad and Matt, as well as all of my other
wonderful family and friends. Without your support, none of this would have been
possible.
iv
ACKNOWLEDGEMENTS
I would like to thank my committee members Dr. Paul Weinhold, Dr. Albert Banes, and
Dr. Peter Mente for their help and advice throughout the course of this research.
I would like to thank Aaditya Devkota for the countless hours of assistance he provided
throughout my time at UNC.
I would like to thank Heather O'Donohue and Dr. David Overstreet, whose aid was
essential to this research.
I would like to thank the UNC Orthopaedics department, specifically Dr. Laurence
Dahners and Reid Draeger for their assistance in this work.
vTABLE OF CONTENTS
LIST OF FIGURES____________________________________________________ vii
INTRODUCTION ______________________________________________________ 1
BACKGROUND REVIEW _______________________________________________ 4
2.1 Tendon Anatomy and Physiology___________________________________________ 4
2.1.1 Function ___________________________________________________________________ 4
2.1.2 Composition ________________________________________________________________ 5
2.1.3 Structure and Organization _____________________________________________________ 7
2.1.4 Mechanical Properties_________________________________________________________ 7
2.2 Tendon Loading ________________________________________________________ 12
2.2.1 Disuse ____________________________________________________________________ 12
2.2.2 Normal Use ________________________________________________________________ 12
2.2.3 Overuse ___________________________________________________________________ 13
2.3 Tendinopathy __________________________________________________________ 13
2.3.1 Degeneration_______________________________________________________________ 14
2.3.2 Inflammation_______________________________________________________________ 14
2.4 Matrix Metalloproteinases _______________________________________________ 14
2.4.1 Collagenase________________________________________________________________ 15
2.4.2 Stromelysin ________________________________________________________________ 15
2.4.3 Tissue inhibitors of metalloproteinases___________________________________________ 16
2.5 Arachidonic Acid _______________________________________________________ 17
2.5.1 Lipoxygenase ______________________________________________________________ 20
2.5.2 Cyclooxygenase ____________________________________________________________ 21
2.6 Prostaglandin E2________________________________________________________ 23
2.6.1 PGE2 effects in tendon _______________________________________________________ 24
2.5.2 PGE2 effects in cervical tissue _________________________________________________ 26
2.5 Clinical Treatment of Tendinopathy _______________________________________ 28
2.5.1 Rest ______________________________________________________________________ 28
2.5.2 Exercise___________________________________________________________________ 29
2.5.3 Pharmaceutical Treatment_____________________________________________________ 29
2.6 Tendinopathy Models ___________________________________________________ 31
2.6.1 In vivo animal and human studies _______________________________________________ 31
2.6.2 In vitro culture studies________________________________________________________ 32
RESEARCH DESIGN AND METHODS___________________________________ 34
3.1 Research Design Specific Aims ____________________________________________ 34
3.1.1 Design and Fabrication of the Tendon Loading Apparatus____________________________ 35
3.1.2 Tissue Culture Methods ______________________________________________________ 38
3.1.3 Statistical Analysis __________________________________________________________ 42
RESULTS____________________________________________________________ 44
vi
4.1 PGE2 Timecourse ______________________________________________________ 44
4.2 Statically Loaded Tendon ________________________________________________ 48
4.3 Nonspecific MMP inhibition ______________________________________________ 51
4.4 Specific MMP-3 Inhibition _______________________________________________ 55
DISCUSSION_________________________________________________________ 61
Appendix 1: Static Loading Device Drawings _______________________________ 67
Appendix 2: Prostaglandin E2 Concentration Calculation_____________________ 71
Appendix 3: Inhibitor Concentration Calculations___________________________ 73
Appendix 3.1______________________________________________________________ 73
Appendix 3.2______________________________________________________________ 74
REFERENCES _______________________________________________________ 75
vii
LIST OF FIGURES
Figure 1: Structural organization of collagen into the microfibril [4] ......................................................... 5
Figure 2: Schematic of tendon microarchitecture[6]..................................................................................... 7
Figure 3: Typical Stress-Strain Curve for Tendon ......................................................................................... 9
Figure 4: Strain Rate Dependent Stress-Strain Curves for Viscoelastic Materials..................................... 10
Figure 5: Hysteresis Loop of Tendon .......................................................................................................... 10
Figure 6: Creep and Recovery .................................................................................................................... 11
Figure 7: Arachidonic Acid Pathway [54] ................................................................................................... 19
Figure 8: Raw levels of prostaglandin E2 in the media of tendons cyclically loaded for three days were
load inducible and load-magnitude dependant. Asterisks on bars indicate a significant difference from the
pre-loading level, while asterisks above bars represent significant differences between groups (P < 0.05)
[30, 91]......................................................................................................................................................... 25
Figure 9: The points of action of pharmaceutical tendinopathy treatments in the arachidonic acid cascade
[4]................................................................................................................................................................. 30
Figure 10: Schematic drawing of tube-stopper apparatus with tendon fascicle pulled through................. 36
Figure 11: Incubator setup with static tissue loading device ...................................................................... 37
Figure 12: Rat tail tendons during statically loaded culture with either suture markers or ink markers and
calibration rods in order to measure strain using a camera and visual strain analysis program ............... 40
Figure 13: Instron failure testing setup....................................................................................................... 42
Figure 14: Maximum stress value reached during tensile failure test of tendon fascicles cultured with and
without PGE2 unloaded for 40 hours. Error bars indicate standard deviations. Asterisks represent
significant differences between groups (2-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05).
Sample sizes were as follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated
fascicles contained 8 fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-
treated fascicles contained 9 fascicles.......................................................................................................... 44
Figure 15: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured with
and without PGE2 unloaded for 40 hours. Error bars indicate standard deviations. Asterisks represent
significant differences between groups (2-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05).
Sample sizes were as follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated
fascicles contained 8 fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-
treated fascicles contained 9 fascicles.......................................................................................................... 45
viii
Figure 16: Strain measured during tensile failure tests of rat tail tendon fascicles cultured with and
without PGE2 unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as
follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated fascicles contained 8
fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles
contained 9 fascicles..................................................................................................................................... 46
Figure 17: Energy measured during tensile failure tests of rat tail tendon fascicles cultured with and
without PGE2 unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as
follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated fascicles contained 8
fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles
contained 9 fascicles..................................................................................................................................... 47
Figure 18: Strain measured before and after 0.3 MPa static load applied in culture to rat tail tendon
fascicles treated with or without PGE2 and unloaded for 24 hours followed by 16 hour static load. Error
bars indicate standard deviation. 4-point stars represent significant difference from own first strain
measurement, and 5-point stars represent significant differences from control at that same time point (2-
way ANOVA, Tukey’s test for multiple comparisons, P < 0.05). Sample sizes were as follows: Loaded,
control group contained 10 fascicles; loaded, PGE2-treated fascicles contained 8 fascicles; unloaded,
control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles contained 9 fascicles. ...... 48
Figure 19: Maximum stress value reached during tensile failure test of rat tail tendon fascicles cultured
with and without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24 hours
followed by 16 hour 0.3 MPa static load in culture. Error bars indicate standard deviation. Asterisks
represent significant differences between groups (1-way ANOVA, Tukey’s test for multiple comparisons, P
< 0.05). Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad
MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50
µM) (n=12)................................................................................................................................................... 49
Figure 20: Young’s Modulus measured during tensile failure test of rat tail tendon fascicles cultured with
and without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24 hours
followed by 16 hour 0.3 MPa static load in culture. Error bars indicate standard deviation. Asterisks
represent significant differences between groups (1-way ANOVA, Tukey’s test for multiple comparisons, P
< 0.05). Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad
MMP inhibitor (bMMPi, 5µM) (n=12). ....................................................................................................... 50
Figure 21: Strain measured during tensile failure test of rat tail tendon fascicles cultured with and without
PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24 hours followed by 16
hour 0.3 MPa static load in culture. Error bars indicate standard deviation. Sample sizes were as follows:
Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM)
(n=12)........................................................................................................................................................... 50
Figure 22: Energy measured during tensile failure test of rat tail tendon fascicles cultured with and
without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24 hours followed by
16 hour 0.3 MPa static load in culture. Error bars indicate standard deviation. Sample sizes were as
follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi,
5µM) (n=12)................................................................................................................................................. 51
Figure 23: Maximum stress value reached during tensile failure test of rat tail tendon fascicles cultured
with and without PGE2 (1µg/ml) and with or without 5 µM of a broad-spectrum MMP inhibitor unloaded
for 40 hours. Error bars indicate standard deviation. Asterisks represent significant differences between
groups (1-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05). Sample sizes were as follows:
Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM)
(n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12). ............................. 52
Figure 24: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured with
or without PGE2 (1µg/ml) and with or without 5 µM of a broad-spectrum MMP inhibitor unloaded for 40
ix
hours. Error bars indicate standard deviation. Asterisks represent significant differences between groups
(1-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05). Sample sizes were as follows: Control
(n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and
PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12). ................................................. 53
Figure 25: Strain measured during tensile failure test of rat tail tendon fascicles cultured with or without
PGE2 and with or without a broad spectrum MMP inhibitor (5µM) unloaded for 40 hours. Error bars
indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2
(1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).............................................................................................................. 54
Figure 26: Energy measured during tensile failure test of rat tail tendon fascicles cultured with or without
PGE2 (1µg/ml) and with or without 5 µM of a broad-spectrum MMP inhibitor unloaded for 40 hours.
Error bars indicate standard deviation. Asterisks represent significant differences between groups (1-way
ANOVA, Tukey’s test for multiple comparisons, P < 0.05). Sample sizes were as follows: Control (n=15),
PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2
(1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12)............................................................. 54
Figure 27: Maximum stress value reached during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-3
inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as
follows: Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor
(sMMP3i, 50 µM) (n=12)............................................................................................................................. 55
Figure 28: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-3
inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as
follows: Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor
(sMMP3i, 50 µM) (n=12)............................................................................................................................. 56
Figure 29: Maximum strain measured during tensile failure test of rat tail tendon fascicles cultured without
PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-3 inhibitor
(50 µM) unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as follows:
Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50
µM) (n=12)................................................................................................................................................... 57
Figure 30: Energy measured during tensile failure test of rat tail tendon fascicles cultured without PGE2
(1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-3 inhibitor (50 µM)
unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as follows: Control
(n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM)
(n=12)........................................................................................................................................................... 58
Figure 31: Maximum stress value reached during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor
(Ilomastat, 5 µM), or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours. Error
bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) plus
broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor
(sMMP3i, 50 µM) (n=12)............................................................................................................................. 59
Figure 32: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor
(Ilomastat, 5 µM), or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours. Error
bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) plus
broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor
(sMMP3i, 50 µM) (n=12)............................................................................................................................. 59
xFigure 33: Strain measured during tensile failure test of rat tail tendon fascicles cultured without PGE2
(1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor (Ilomastat, 5 µM),
or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours. Error bars indicate
standard deviation. Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) plus broad MMP
inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM)
(n=12)........................................................................................................................................................... 60
Figure 34: Energy measured during tensile failure test of rat tail tendon fascicles cultured without PGE2
(1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor (Ilomastat, 5 µM), or
with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard
deviation. Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) plus broad MMP inhibitor
(bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12)..... 60
Figure 35: Tendon hanging rod for statically loading tendon in incubator................................................ 67
Figure 36: Stopper holder device for incubator.......................................................................................... 68
Figure 37: Calibration rods for visual strain analysis................................................................................ 69
Figure 38: Stopper holder device assembled with calibration rods............................................................ 70
xi
LIST OF ABBREVIATIONS
AA Arachidonic Acid (all-cis-5,8,11,14-eicosatetraenoic)
COX Cyclooxygenase
DMEM Dulbucco’s Modified Eagle Medium
DMEM-H  Dulbucco’s Modified Eagle Medium (High Glucose)
E Elastic Modulus (Young’s Modulus)
GAG Glycosaminoglycan
J Joule
MMP Matrix Metalloproteinase
MPa Megapascals (kg*m/s2)/m2 x 106
mRNA Messenger ribonucleic acid
NSAID Non-Steroidal Anti-Inflammatory Drug
PGE2 Prostaglandin E2
TIMP Tissue inhibitor of metalloproteinase
VDA Video Dimension Analyzer
VSA Video Strain Analysis
Chapter 1
INTRODUCTION
Tendon overuse injuries are a common medical problem both occupationally and
athletically. The etiology of these injuries remains mostly uncharacterized despite their
prevalence. The most frequently prescribed medications for addressing tendinopathy
symptoms are nonsteroidal anti-inflammatory drugs (NSAIDs), which act to reduce pain
and inflammation. However, the role of inflammation in tendinopathy has not been
definitively determined. Though repetitive loading has been shown to increase
inflammatory mediators in tendon tissue, biopsies from damaged tendons fail to show
inflammatory cell infiltration. One such inflammatory mediator that has been implicated
as a precursor to tendon overuse injury development is prostaglandin E2 (PGE2).
PGE2 is intimately involved in several biological processes and is found in many
biological tissues, including tendon and the cervix in females. In tendon, PGE2 has long
been characterized as a key factor in the development of tendinopathy over time, and in
the cervix, PGE2 production is increased just before childbirth. Neither mechanism of
PGE2 action is well understood; however treatments based on assumptions of PGE2
activity in these various scenarios are used regularly in the clinic. NSAIDs are prescribed
in tendinopathy patients in order to decrease PGE2 and therefore hopefully lessen the
2condition, and PGE2 gels are used to stimulate softening of the cervix and permit
childbirth when applied to the cervix directly.
To investigate the effect of PGE2 on tendon more closely, we will employ a rat
tail tendon model under static or no load conditions. The rat tail tendon model has been
well-documented as an explant model for tendon in vitro, including static loading and
stress-deprivation conditions. The static load will allow us to investigate the creep
properties of tendon, which may play a role in pathology of tendon overuse injury. Since
collagenase has been shown to be unable to act on tendon in uniaxial tension, the
unloaded group will allow all MMPs to freely act on the tendon so their effects can be
quantified biomechanically. All changes in tissue properties will be assessed via a tensile
failure test immediately after culture. Decreases in mechanical properties are a clinically
relevant symptom of tendinopathy, as tendons with overuse-type injuries are more likely
to rupture during normal activities.
Collagenase and stromelysins have been implicated in material property changes
of the cervix with PGE2 exposure. Further studies into cervical remodeling after PGE2
application has lead to a direct link between MMP-3 expression and changes in cervical
tensile strength through pregnancy. No such investigation has been done to characterize
PGE2’s effects on MMP-3 activity in tendon, nor has the specific effect of MMP-3 in
tendon been characterized. MMP-3 is a potent activator of other MMPs, including
collagenases, and itself has the ability to cleave extracellular matrix proteoglycans.
Once the effects of loading and unloading tendon in the presence of PGE2 are
established, we attempted to characterize the mechanisms of PGE2’s actions. Culturing
rat tail tendons with PGE2 and a broad-spectrum MMP inhibitor allowed effects due to
3enzymatic degradation to be determined. Once PGE2 effects were shown to be
influenced by decreasing MMP activity, the effects of MMP-3 specifically were
investigated by adding a specific MMP-3 inhibitor to the culture system.
The general objective of the research presented here is to determine the effect of
exogenous PGE2 exposure on tendon biomechanical properties during unloaded and
statically loaded culture. We have hypothesized that PGE2 is acting to decrease the
biomechanical properties of rat tail tendon fascicles via increased MMP activity.
Chapter 2
BACKGROUND REVIEW
2.1 Tendon Anatomy and Physiology
2.1.1 Function
Tendons are fibrous connective tissue that works to transmit loads across joints
and facilitate motion. Tendons are similar to ligaments, with their main distinction being
that tendons connect muscle and bone while ligaments connect bone and bone and are not
subject to the same load levels as tendon. Tendons therefore have a muscular insertion
site, termed the myotendinous junction, as well as a bone insertion side, or
osteotendinous junction.
Tendons are passive tissues, which do not actively contract to generate forces.
Instead, they transmit forces from muscles to bones to generate motion. Tendons are
ideally suited for joints where space is limited, and their higher tensile strengths allow
them to support large loads with minimal deformation. This process is highly efficient in
that tendons forces are transmitted from muscle to bone with little energy lost to tendon
stretching. They also absorb shock by damping sudden motion which limits damage to
muscles and limits sudden, volatile motor stimuli [1]. A final role of the tendon is to
store elastic energy, which can be converted to kinetic energy by elastic recoil resulting
movement.
52.1.2 Composition
The majority of tendon is type I collagen (86%), with trace amounts of type III
and V [2]. The main amino acids are glycine (33%), proline (15%), and hydroxyproline
(15%). Proline and hydroxyproline give collagen fibrils their strength and therefore
regions devoid of these amino acids give collagen its flexibility. Regions with the
sequence Gly-Pro-Hypro have the greatest rigidity [3] and are the basis for the stability of
the collagen molecule via intermolecular cross links formed by the activity of lysyl
oxidase. The other major protein in tendon is elastin (2%).
Figure 1: Structural organization of collagen into the microfibril [4]
The other major constituents of tendon tissue are proteoglycans which compose
1% to 5% of tendon dry weight. These molecules are extremely hydrophilic and bind
water within the tendon. They are made up of a protein core with glycosaminoglycan
6(GAG) side chains. Decorin is a small proteoglycan located on the surface of collagen
fibrils, and has been proposed to connect neighboring fibrils. Decorin has also been
implicated in regulating collagen fiber formation in vivo. It is the predominant
proteoglycan in the tension-bearing portion of the tendon, whereas two types of small
proteoglycans, decorin and biglycan, as well as large proteoglycans are found in the
portion of tendon which undergoes compression.
The inorganic component of tendon, roughly 0.2% of the dry weight, include
copper, manganese, magnesium, cadmium, cobalt, zinc, nickel, lithium, lead, fluoride,
phosphor and silicon. Their roles are various, some yet unknown, but some well defined
ones include copper’s role in cross-linking, manganese’s role in molecule synthesis and
calcium’s role in signaling [5].
Finally, the cells of tendon are called tenocytes, which are specialized fibroblasts
that maintain the collagen structure of the tissue. About 95% of the cells found in tendon
are tenocytes; however there are also chondrocytes at insertion points of the tendon,
synovial cells in the tendon sheath, vascular cells and inflammatory cells during certain
pathologic conditions.
72.1.3 Structure and Organization
Figure 2: Schematic of tendon microarchitecture[6]
The collagen fibrils are long rod shaped structures composed of numerous triple-
helix polypeptide chains. The chains are surrounded by a thin layer of proteoglycans
(PGs) and glycosaminioglycans (GAGs). The molecule is roughly 300nm long and 1 –
2nm wide. Each molecule overlaps its neighbors by 67nm or roughly 25% and is often
referred to as the quarter-staggered array. This 67nm region is comprised of an overlap
region of 40% and a hole region of 60% [3]. These fibrils are surrounded by more PGs
and GAGs that are different from those surrounding the alpha chains [1].
2.1.4 Mechanical Properties
Tendons are capable of supporting extremely large loads with minimal strain.
Tendons are passive tissues and cannot actively contract to generate forces. Thus, the
8ability of tendons to support large loads is dependent upon the properties of the
extracellular matrix molecules: collagen, proteoglycan and water.
2.1.4.1 Failure Properties
Generally, mechanical properties of tendons are evaluated in vitro by uniaxial
tension tests. A typical failure curve from this type of test is shown in Figure 3. The
shape of the curve is due to the viscoelastic properties of tendon. At low strains, less stiff
elastic fibers are supporting the majority of the load and the crimped pattern is gradually
straightened. This requires minimal force to see strains of 0-2% develop in the tissue and
is known as the toe region [7]. . After the crimp is straightened, the tendon is much
stiffer. This linear region of the stress-strain curve ranges from 1.5 – 4% strain and is
elastic so the strain is fully recoverable [7, 8]. Past 4% strain is the failure region where
non-recoverable damage to individual fibrils occurs as they begin to shear past each other
and cross links break in an unpredictable fashion [4, 7, 9]. This continues until enough
fibrils and cross-links are damaged to cause macroscopic failure, which commences
around 8-10% stain [7, 9].
9Figure 3: Typical Stress-Strain Curve for Tendon
2.1.4.2 Strain Rate Dependence
The viscoelastic nature of tendon results in a load-rate dependent stiffness of the
tissue. As tendons are strained, fluid in the collagen fibers flows out of the tendon. Thus,
at high strains a majority of the applied load is bore by the collagen. However, if the
tendon is stretched rapidly, the fluid is unable to flow out completely resulting in
increased stiffness [10]. This effect is illustrated in Figure 4.
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Figure 4: Strain Rate Dependent Stress-Strain Curves for Viscoelastic Materials
2.1.4.3 Hysteresis
Another viscoelastic behavior of tendon is that of preconditioning, a phenomenon
where the first few cycles of load result in greater work being done to stretch the tendon
than is recovered when the tendon is allowed to relax. Hysteresis is the difference in
energy imparted to and returned from a material, where this energy is lost from the
system as heat [4]. The hysteresis effect on stress is shown in Figure 5.
Figure 5: Hysteresis Loop of Tendon
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2.1.4.4
Tendon will undergo creep with application of a constant applied load, as shown
in Figure 6. Physiologically, this is beneficial, as during muscle contraction the tendon-
muscle unit length remains constant. As the tendon gradually lengthens, the muscle can
relax. This reduces muscle fatigue, and increases performance during contraction [4].
However, Goldstein et al. have shown that creep may be an important factor in
cumulative tendon disorders [11]. Prolonged creep can lead to tensile failure at much
lower stress levels than a dynamic failure test, and in tendon this time is depended upon
the initial strain amount placed on the tendon [12].
Figure 6: Creep and Recovery
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2.2 Tendon Loading
2.2.1 Disuse
Immobilization has serious negative effects on tendon. Examining immobilized
joints of both animals and humans has shown reductions in GAG content and increased
collagen type III, resulting in decreased tensile strength, elastic stiffness, total weight and
energy to failure [1, 13-17]. Also, MMP-1 expression is significantly upregulated with
stress deprivation in animals [18]. Moreover, the tensile loading tendon in vitro has
shown to have a protective effect by inhibiting the ability of collagenase to cleave
collagen molecules in loaded tendon, as well as protecting collagen bundles from
inflammatory cell-induced deterioration [19].
2.2.2 Normal Use
Long-term physical activity improves the tensile mechanical properties of tendons
[16]. Results from normal activity result in the opposite effects seen with tendon disuse.
Training induced changes include increased GAG content, decreased collagen cross-
linking and increased collagen fiber alignment [16]. These changes have been shown to
increase load at failure in rabbits [20].
Using microdialysis, in vivo measurements of human Achilles tendon response to
exercise has been measured. Inflammatory mediators prostaglandin E2 and thromboxane
B2 were increased during the exercise, and levels remained raised after a 60 minute
recovery period [21].
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2.2.3 Overuse
Although appropriate training or exercise produces positive effects on tendons,
excessive loading during vigorous exercise or occupational activity with a high frequency
and/or long duration may induce tendon degeneration. In rats, extensive training over a 4
week period decreased the elastic modulus of the supraspinatus tendon, and the stress
level at failure [22]
Overuse injuries in tendon are thought to arise from repetitive tensile loading that
results in subfailure microinjuries, and the cumulative effect results in deterioration [23].
The molecular mechanisms of this degeneration are not well understood, though fibril
damage has been linked to increases in collagenase mRNA and protein levels [24]. The
failure of an individual fibril results in a mechanobiological understimulation of the
tenocytes associated with that fibril, resulting in the effects seen in stress deprived tendon
including increased collagenase. This may increase damage to the extracellular matrix
and increase the risk for further damage as load is repetitively applied [25].
2.3 Tendinopathy
Tendinopathy is the general term used to describe disorders of the tendon, such as
tendonitis, tendinosis and paratendinitis. The pathogenesis of tendinopathy is difficult to
study in patients, as tendon biopsies are only obtained after the condition has become
chronic. However, it is assumed that tendinopathy develops with repetitive mechanical
loading and some molecular mechanisms that are not well characterized. Load inducible
cellular responses that likely play a key role in driving tendon degeneration are cytokines,
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inflammatory mediators and MMPs [26, 27]. There is some discrepancy as to the role of
inflammation versus degeneration in development of the disease.
2.3.1 Degeneration
MMPs are the primary proteins used to remodel the collagen matrix, and thus
their potential role in tendinopathy is direct and obvious. They can be converted from an
inactive proenzyme to active enzymatic form by specific MMPs, and thus a positive
feedback loop can be activated that leads to excessive degeneration. Injection studies of
collagenase have shown tendinosis like degeneration, similar to that observed during
tendon injury, thus implicating the collagenase MMPs as potential tendinopathy
contributors [28, 29].
2.3.2 Inflammation
Cytokines and inflammatory mediators, such as IL-1 and PGE2, act indirectly
through a host of cascades that can lead to tendinopathy. Injection models of both
cytokines and inflammatory mediators have shown tendinosis type degeneration [28, 30].
Though their exact mechanism in tendinosis is unclear, and the exact role has been
questioned [31], inflammatory molecules have long been implicated as key to early
development of tendinopathy.
2.4 Matrix Metalloproteinases
Degradation of extracellular matrix (ECM) proteins is initiated by zinc and
calcium dependent endopeptidases called MMPs. These enzymes are secreted from cells
in the pro form, and must be activated before degrading ECM components [32]. The
mechanism of proMMP activation is poorly understood in vivo.
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There are 23 members of the MMP family, and they are divided into groups based
on substrate. The four main MMP classes are collagenases, gelatinases, stromelysins and
membrane type MMPs.
2.4.1 Collagenase
MMPs with collagenase activity include MMP-1, 2, 8, 13 and 14 [33, 34]. The
importance of collagenase in development of degenerative tendinopathy has not yet been
fully investigated.
MMP-1 mRNA has been shown to be increased in vitro, as tenocytes are exposed
to fluid shear stresses, and in vivo, in ruptured supraspinatus tendon [35, 36]. MMP-1
increases are also seen in stress deprived tendons in culture, and can be eliminated by
exposing the tenocytes to a cyclic tensile load [18]. This same MMP-1 mRNA inhibition
is seen in rat tail tendons cultured in static loading conditions [37]. Thus, the type of
loading (shear versus cyclic and static tensile loads) seems to be an important factor in
MMP-1 expression in tendon.
MMP-2 has been shown to degrade ECM at the tendon edges in an acute tear
animal model [38].
2.4.2 Stromelysin
The stromelysins consists of MMP-3, 10, and 11. These MMPs degrade
proteoglycans, fibronectin, casein, and collagen types III, IV and V. They are also potent
activators of other MMPs (such as MMP-1, 3, 7, 8, 9 and 13), and thus have the potential
to be an important regulator of tendon remodeling.
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A decrease in MMP-3 mRNA is associated with the changes seen during
tendinopathy, along with a decrease in the mRNA of a number of TIMPs [39]. This may
indicate a potential role for MMP-3 in non-pathologic tissue maintenance. Investigation
into the timing for MMP-3 activity of tendon could potentially uncover more information
about the onset of tendinopathy.
In vitro studies have shown rabbit tendon cells increase expression of MMP-3
with exposure to shear stress [35]. Shear stress on tenocytes may contribute to
tendinopathy by way of action of MMPs and COX-2 [35, 40]. It has been suggested that
certain individuals may have an increased susceptibility to tendon disorders, due, in part,
to their tenocyte’s altered production of MMP-3 in combination with a decrease in TIMP
production [40].
2.4.3 Tissue inhibitors of metalloproteinases
MMP activity is inhibited by tissue inhibitors of metalloproteases (TIMPs). In
normal tendon, MMPs and TIMPs are balanced to regulate tissue remodeling. However,
tissue samples from patients exhibiting tendinopathy symptoms show an increase in
MMP mRNA as well as a decrease in TIMP mRNA [41, 42]. Table 1 indicates some
common MMPs and TIMPs found in tendon.
TIMP-1 is not normally present, but its expression is increased at the site of an
acute tear. Therefore, it may be responsible for inhibiting excessive MMP-2 degradation
of tendon [38]. TIMP-1 is also thought to be an important regulator of MMP-1, and a
significant decrease in TIMP-1 activity is seen in tendinopathic tendon [43].
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Table 1: Main roles of some MMPs and TIMPs in tendon [40]
MMP/TIMP Main Roles
MMP-1 
Degrades type I collagen
Up-regulated in acute tendon tears
Up-regulated in tendinopathy
Up-regulated in response to shear stress
Up-regulated during stress deprivation
Down-regulated in response to cyclic strain and static tensile load
MMP-2 
Up-regulated in tendinopathy
May be up-regulated or down-regulated in complete tendon tears
Inhibits TIMP-1 and TIMP-2 in response to exercise
MMP-3 
Plays a major role in maintenance and remodeling of normal tendon
Down-regulated in tendinopathy and complete tendon tears
Up-regulated in response to shear force
MMP-13 Up-regulated in complete tendon tears
MMP-9 Up-regulated following exercise
TIMP-1 
Down-regulated in tendinopathy
Up-regulated transiently following an acute tendon tear
Inhibits excessive degeneration by MMP-2 
TIMP-2 Down-regulated in tendinopathy and complete tendon tears
2.5 Arachidonic Acid
Arachidonic acid is an omega-6 fatty acid with a 20-carbon chain and 4 cis double
bonds. It is present in the phospholipid bilayer of cells, and is essential to membrane
fluidity at physiologic temperatures. Arachidonic acid is the initial molecule in a cascade
that ends in prostaglandin E2, along with a variety of other prostanoids.
The arachidonic acid cascade can be started by an inflammatory response.
Initially, phospholipase A2 releases free arachidonic acid from the lipid bilayer. Once
freed, arachidonic acid can undergo enzymatic conversion to prostaglandins,
thromboxanes, prostacyclins and leukotrienes. However, unaltered arachidonic acid has
been suggested to have several physiologic roles.
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At rest, the concentration of free arachidonic acid is low. When exogenous
arachidonic acid is introduced it has been shown to be absorbed and metabolized by the
cells [44]. Whether artificially placed or naturally occurring, free arachidonic acid in the
cytoplasm has three fates: storage in the cell membrane, diffusion outside of the cell, or
metabolism.
When arachidonic acid moves outside the cell it may be involved in a range of
functions. The leukocyte NADPH oxidase can be activated to reduce molecular oxygen
to superoxide by micromolar concentrations of arachidonic acid [45, 46].
Polyunsaturated fatty acids in general play a role in many ion channels. For example,
mechano-sensitive K+ channels, Ca2+ channels, gap junctions, and a dopamine transporter
have all been reported to show an action of polyunsaturated fatty acids [47-50]. More
specifically, a member of the K+ channel is called the TWIK-related arachidonic acid-
stimulated K+ channel or TRAAK [51]. Arachidonic acid has been shown to inhibit cell
proliferation and initiate apoptosis [52]. Arachidonic acid-induced apoptosis may be the
mechanism behind the protective effect of NSAID usage on the incidence of colon
carcinoma, due to arachidonic acid accumulation in patients taking these drugs [53].
Arachidonic acid’s many broad physiologic effects can be attributed to its simple
structure and many close chemical analogues. Any specificity in its actions may be
simply due to its relative specificity of release from the membrane in certain situations
when compared to other fatty acids. The concentration of arachidonic acid required to
elicit the above biologic responses is usually on the micromolar level, and when
compared with the nano- or picomolar levels of the prostaglandins or leukotrienes
required to evoke cellular responses, arachidonic acid is clearly less potent.
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Arachidonic acid metabolism is the more interesting fate of the freed molecule for
the work presented here, the pathway is illustrated in Figure 7. The arachidonic cascade
is driven by three main enzymes: cytochrome P450, lipoxygenase and cyclooxygenase.
Cytochrome P450 converts arachidonic acid to epoxyeicosatrieonic fatty acids
(EpETrEs). Lipoxygenase and cyclooxygenase convert arachidonic acid to eicosanoids,
including leukotrienes, prostanoids and thromboxanes.
Figure 7: Arachidonic Acid Pathway [54]
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2.5.1 Lipoxygenase
Lipoxygenases are an entire family of enzymes that act to oxygenate arachidonic
acid. The lipoxygenase pathway is the metabolic transformations that arachidonic acid
undergoes during conversion by these enzymes.
The three main isoforms of lipoxygenase are 5-Lipoxygenase (5-LO), 12-
Lipoxygenase (12-LO), and 15-Lipoyxgenase (15-LO) forming 5-, 12-, and 15-
hydroperoxy-eicosatraenoic acid (HPETE), respectively. The lipoxygenase pathway
refers to the metabolic transformation that the HPETEs undergo. HPETEs are converted
to lipoxins, 12-HETEs and leukotrienes of the 4 series.
The 5-LO pathway produces leukotrienes, which are eicosanoid lipid
mediators that act principally on G protein coupled receptors. They are primarily
involved in allergic reactions and inflammatory conditions, such as rheumatoid arthritis,
psoriasis and asthma. Leukotriene B4 is a chemoattractant for neutrophils, macrophages
and other inflammatory cells and induces adhesion of these cells to the vascular
endothelium [55]. Leukotrienes C4, D4 and E4 increase vascular permeability and
contract smooth-muscle cells [55]. 5-LO requires an activator protein from the nuclear
membrane known as the 5-lipoxygenase activating protein (FLAP).
Little is known about the 12-LO pathway, it was originally isolated in human and
animal platelets and has since been isolated in porcine leukocytes and other tissues [56-
58]. Its biologic functions have been shown to range from cardiovascular to neurological
applications, but it does not produce potent biological mediators such as prostaglandins,
thromboxanes and leukotrienes [59-61]. Its main role is regulating cellular
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concentrations through apoptosis or proliferation in inflammatory and normal tissue
maintenance.
HPETEs are converted to lipoxins A4 and B4 via the 15-LO pathway. Lipoxins
are eicosanoids that appear at the end of an inflammatory response and are considered the
“braking signals” of inflammation. The lipoxins have been shown to have vasoactive
properties at nanomolar concentrations; stimulating vasodilatory responses in some
tissues and vasoconstricting responses in others [62]. They also have potential roles as
immunoregulators and have been shown to inhibit cell migration and proliferation [62,
63].
2.5.2 Cyclooxygenase
Cyclooxygenase (COX), also known as prostaglandin H synthase, is the enzyme
required for conversion of arachidonic acid to prostaglandins. It catalyzes the production
of prostaglandin G2 (PGG2) from arachidonic acid, and then peroxidase reduces PGG2 to
PGH2. Then several cell-dependent synthases convert PGH2 into the various prostanoids.
There are three isoforms of the COX enzyme, COX-1, COX-2 and, recently discovered,
COX-3 which is a COX-1 variant.
It has been shown that COX-1 is constitutively expressed in many cells, whereas
COX-2 is induced by certain stimuli, such as inflammation, pain, fever and cancer.
COX-3 appears to be selectively inhibited by acetaminophen over COX-1 and -2, and this
inhibition has been presented as a possible mechanism in pain and fever reduction [64].
Determining the specific functions of COX is key, as these enzymes are the main targets
for non-steroidal anti-inflammatory drugs (NSAIDs).
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Both COX-1 and COX-2 are integral membrane proteins in the endoplasmic
reticulum (ER) and perinuclear envelope, with COX-1 more enriched in the ER, and
COX-2 in the perinuclear envelope [65, 66].
The role of COX in physiologic and pathologic conditions has been thoroughly
investigated with the use of mice deficient in COX-1 or COX-2. COX-2 deficient mice
show a milder inflammatory response to rheumatoid arthritis, carageenan-induced edema
and subdermal air pouch then COX-1 deficient or wild-type mice [67, 68]. However,
arachidonic acid-induced edema is milder in COX-1 deficient mice than in COX-2
deficient mice, indicating both isoforms play a role in some type of inflammation [69,
70].
These mouse models have also been used to study the role of COX in female
reproduction. COX-1 deficient mice have significantly prolonged gestation periods [71].
COX-2 knockout mice have many female reproductive problems with ovulation,
fertilization and implantation [72].
After conversion of arachidonic acid to PGH2 by COX and peroxidase, specific
synthases convert PGH2 to thromboxanes, prostacyclins and prostaglandins D, E, and F.
Thromboxane is produced by platelets via thromboxane-A synthase, and acts as a
vasoconstrictor and plays a role in clot formation. Thromboxane is in homeostatic
balance with prostacyclins, which is produced in endothelial cells via prostacyclin
synthase. Prostacyclin acts as a vasodilator and prevents platelet formation and clotting.
Prostaglandins are produced in most cell types via prostaglandin synthase. Their main
action is in inflammation mediation; however they also regulate calcium movement, cell
growth and hormone regulation.
23
2.6 Prostaglandin E2
PGE2 is an inflammatory mediator that has vasodilatory effects at locations of
inflammation. It also acts to increase cAMP levels in neutrophils and macrophages and
inhibits their functional response to other inflammatory stimuli. With respect to tendon,
PGE2 has been shown to decrease collagen type I production as well as increase MMP-1
and 3 expression and synthesis [73]. PGE2 is also utilized clinically to induce cervical
softening during the onset of labor. The role of collagenase in these changes has not been
definitively shown [74-76], but MMP-3 increases have been identified as a primary cause
of cervical tensile strength changes with PGE2 exposure [77].
PGE2 acts through EP receptors. These are G-protein-coupled receptors which
are classified into four subtypes: EP1, EP2, EP3 and EP4 [78]. Once activated, each
receptor initiates a unique signal transduction mechanism. EP1 stimulates intracellular
calcium, EP2 and EP4 activate increases of intracellular cAMP levels, and EP3 has been
implicated in multiple signal pathways [79]. In fibroblasts, PGE2 has been shown to act
through upregulation of specific EP-receptors to achieve various effects. Lung
fibroblasts, which activate EP2 receptors to reduce collagen type I expression, show
decreased ability to suppress collagen synthesis with PGE2 exposure in EP2-deficient
mice [80]. It has been proposed that the specific upregulation of EP4 receptors in tendon
fibroblasts may trigger inflammatory signaling pathways leading to tendinopathy [81]. In
the cervix, EP4 has been implicated as the PGE2 receptor involved in producing the
tissue changes at term [82].
24
2.6.1 PGE2 effects in tendon
PGE2 has been identified in tendon as a central mediator in inflammation and
pain [83]. Models of tendinopathy have provided evidence that PGE2 production may
be an important step on tendinopathy development [30, 84, 85]. Many studies, in vivo
and in vitro, have been conducted in order to better understand the cellular and molecular
mechanisms of tendinopathy. It has been shown that PGE2 is released by human tendon
fibroblasts after cyclic mechanical stretching in vitro [85, 86], and PGE2 has also been
quantified in the peritendinous space after exercise in an in vivo study [21].
PGE2 has been shown to decrease human patellar tendon fibroblast proliferation
and collagen production when cultured in vitro [73]. Furthermore, in vivo studies in
rabbits have shown that PGE2 injection into the patellar tendon leads to disorganization
of the collagen matrix and decreased diameter of collagen fibrils [30]. Interestingly,
however, there was an absence of inflammatory cells in the tendon after one week, and
tendon mechanical properties were not assessed. The observed changes in these tendons
has been proposed to be due to an up regulation of collagenase by PGE2 [30]. PGE2 is
thought to mediate MMP-3 production and activation in fibroblasts [81, 87].
Previous studies in our laboratory have shown a trend for exogenous PGE2
exposure to increase accumulated strains during cyclical loading in an avian tendon
explant model. This is consistent with past results from cultured fibroblast and human
micro-dialysis studies which both showed increased PGE2 after loading [21, 84, 88, 89].
The studies in our lab resulted in load-induced PGE2 levels similar to the human tissue
levels seen in the micro-dialysis studies [27]. The established role of PGE2 as an
inflammatory mediator coupled with its increase with loading have prompted the
consideration of excessive PGE2 production to play a role in the pathology of overuse
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tendinopathy [90]. Furthermore, application of COX inhibitors in our laboratory’s model
was shown to significantly decrease accumulated strains with cyclical loading thus
providing additional evidence of a role of PGE2 in facilitating the lengthening of dense
connective tissues. Evaluation of mechanical properties from failure tests from this study
revealed the midsubstance stiffness of the tissue to be decreased and the strains at
ultimate load to be increased with PGE2 treatment. However, no differences in strength
were observed with PGE2 treatment, which may provide evidence that PGE2 acts
through a pathway other than collagenase activation.
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Figure 8: Raw levels of prostaglandin E2 in the media of tendons cyclically loaded for three days
were load inducible and load-magnitude dependant. Asterisks on bars indicate a significant
difference from the pre-loading level, while asterisks above bars represent significant differences
between groups (P < 0.05) [30, 91].
The continuing question of PGE2’s role in tendinopathy has led to several
injection studies investigating the ability of PGE2 or PGE1 to initiate degenerative
changes similar to overuse tendinopathy. While histological studies suggested these
injections could initiate degenerative changes [31], a recent study evaluating mechanical
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properties found structural strength and stiffness to increase at 8 weeks after 4 weeks of
injection [92]. Though this seems contradictory, perhaps PGE2 is activated for tissue
remodeling which may be observed as degenerative in the short-term, yet improves
material properties over time. The concept of PGE2 having a role in activating tissue
remodeling has precedence in studies of bone, where increased bone mass has been
observed following prostaglandin injections [93]. It has been suggested that tendon may
experience a transient period of weakness as the tendon remodels, so excessive activation
of remodeling by PGE2 may actually make the tissue more susceptible to further injury
when it is being repetitively loaded [90]. Further investigation into the true effects of
PGE2 in the short and long-term is needed.
2.5.2 PGE2 effects in cervical tissue
In the cervix, extensive remodeling occurs before the onset of parturition referred
to as “ripening”. This process allows gradual structural modification that will enable the
cervix to stretch without breaking during labor. Similar to tendinopathy, the mechanisms
involved in this process are not well understood. In a clinical setting, PGE2 and its
analogs are used to induce the cervical ripening process and initiate labor because PGE2
production is increased in normal parturition [94-96].
Studies of the use of PGE2 gels to promote cervical ripening have suggested two
main effects by which PGE2 may be acting to allow distension of the cervix: increased
MMP activity and an increase in proteoglycan concentrations [75]. However, in a study
of human cervical tissue, PGE2 treatment did not increase collagenase nor were typical
collagen cleavage products indicative of enzymatic activity found in the samples [75].
27
Furthermore, biomechanical studies of PGE2 cervical ripening in the rat have suggested
that changes associated with PGE2 treatment are not consistent with findings observed
during exposure to collagenase. Buhimischi et al. compared physical and biomechanical
characteristics of rat cervices exposed to PGE2 via gel in vivo and those cultured with
collagenase in vitro, and found that the PGE2 exposure did not result in similar
mechanical properties to those cervices cultured with collagenase. They found PGE2
increased plasticity, compliance and strength of the rat cervix, while collagenase had the
opposite effect [74]. While some studies have found collagenase activity to be increased
after PGE2 application to promote cervical ripening, the time period over which this
activity is increased is relatively brief suggesting other mechanisms of lengthening may
be occurring [94].
In vivo application of PGE2 to the cervix stimulates increases in proteoglycan
concentration [97]. Due to the insufficient evidence that collagenase up-regulation is a
main component of cervical ripening, it is possible that the increase in proteoglycan
synthesis is a key factor in altering cervix mechanical properties. As in tendon, decorin
binds to the collagen fibrils of the cervix, especially during the ripening process. It has
been shown that the more decorin found within the extracellular matrix, the greater the
rate of creep of the tissue [98].
A possible role of stromelysins, specifically MMP-3, in PGE2-induced cervical
ripening has recently been noted. Increased collagenase mRNA levels seen at the onset
of active labor fails to explain the progressive decrease in cervical tensile strength during
the second half of gestation. These changes may be due to tissue remodeling that is
mediated by MMP-3 [77]. PGE2 application in the cervix has not been shown to increase
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MMP-3 expression or synthesis, but it has been shown to significantly increase the
amount of active enzyme in the tissue [77].
PGE2, however, will not induce cervical ripening when applied mid-gestation in a
rat model [77]. There is an increase in expression of the EP4 type of the four PGE2
receptors near term, and it is thought that ripening is mediated through activation of this
particular receptor [99, 100]. Using specific agonists for EP1-4, it has been confirmed
that the effects seen by PGE2 application in the cervix are only mimicked by activation
of the EP4 receptor [82].
2.5 Clinical Treatment of Tendinopathy
Because of the relative mystery behind tendinopathy pathogenesis, there is not a
definitive treatment. However, the first approach is generally to use nonoperative,
conservative means to alleviate symptoms [27]. Focusing treatment to correct causative
factors would be ideal.
2.5.1 Rest
With the structural damage incurred in tendinopathy, rest may allow time for the
tendon to repair partial tears. However, tendon disuse does have negative consequences,
including lowered metabolic activity, increased collagen turnover, reduced cross-linking,
collagen disorientation, and decreased GAG content [1, 16, 101]. This can result in
mechanical property changes, i.e. decreased tensile strength, elastic stiffness, total weight
and energy to failure [1, 13-16].
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2.5.2 Exercise
If the pain associated with a patient’s tendon disorder is not too severe, a simple
decrease in frequency, intensity and duration of the aggravating activity may suffice [27].
Controlled mobilization has been shown to enhance tendon strength properties, so
loading below damage levels can be beneficial during healing [15, 102].
2.5.3 Pharmaceutical Treatment
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently used
pharmacologic substance in treating tendinopathy [27]. NSAIDs are known to reduce
pain associated with tendon disorders [103]. There is much contradictory evidence about
the efficacy of NSAID use, as well as considerable data outlining the potential harms of
these drugs.
NSAIDs inhibit the enzyme COX, and thus inhibit prostaglandin synthesis, which
results in analgesic and anti-inflammatory effects. COX-1 is constitutively expressed in
many tissue types, and has a variety of physiologic roles including maintaining gastric
mucosa, regulating renal blood flow, and influencing platelet aggregation. COX-1
inhibitors have been implicated in gastrointestinal bleeding and ulcering. No benefits of
COX-1 inhibition from NSAIDs have been seen [104]. The pathway on which NSAIDs
act is shown in Figure 9.
Meanwhile, COX-2 is mainly an inducible enzyme present exclusively during
inflammation. Discovery of this isoform led to development of COX-2 specific
inhibitors to effectively block inflammation and pain without disturbing normal tissue
functions. Initially, these drugs appeared to function with significantly fewer serious
gastrointestinal adverse effects than non-selective NSAIDs [54]. However, over time
coxibs have been associated with changes in blood pressure that lead to increased risk of
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heart attack, thrombosis and stroke. For this reason, certain coxibs have been banned or
permanently withdrawn from the market.
Figure 9: The points of action of pharmaceutical tendinopathy treatments in the arachidonic acid
cascade [4]
Corticosteroids are another commonly used treatment in musculoskeletal
conditions. They can be injected directly in the tendon sheath to alleviate inflammation
by blocking both COX and lipoxygenase pathways of arachidonic acid metabolism.
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2.6 Tendinopathy Models
2.6.1 In vivo animal and human studies
Animal models of tendinopathy can either attempt to induce degenerative changes
through physical or chemical means. Physical attempts to model tendinopathy require
exercising an animal with a high enough frequency over a long enough period of time to
induce overuse changes in the tendon. For example, rabbit hind paws were passively
exercised for 2 hours, 3 times a week, for up to 6 weeks. This caused the Achilles tendon
to show increased numbers of capillaries, increased inflammatory cell infiltration, edema,
and fibrosis [105]. Overuse has also been modeled in rats, by engaging the animals in a
reaching task 2 hours a day, 3 times a week, for up to 8 weeks. This model showed an
increase in macrophage infiltration of the upper-extremity tendons, and the collagen
fibrils becoming frayed [106]. Finally, treadmills have also been used to exercise rats.
This study showed a decrease in supraspinatus tendon cell number, as well as
disorganization and damage of collagen fibers at 8 weeks and a reduction in stress at
failure [22].
These animal models of tendinopathy have shown that repetitive mechanical
loading causes inflammation in the tendon. The investigators conclude that destruction
of the tendon is due either to mechanical damage, biochemical mediators, or both.
However, because exercise animal models for tendinopathy can have a high cost and
show inconsistent results due to the inability to precisely control and normalize the loads
seen in the tissues, the use of injection animal models of tendinopathy has been
investigated.
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In one animal model, PGE1 was injected into the peritendinous space of the rat
patellar tendon, and was shown to induce inflammation and degeneration in and around
the tendon [91]. Likewise, a study that injected PGE2 into the midsubstance of rabbit
patellar tendons induced profound changes in the tendon extracellular matrix [30].
However, previous work in our laboratory showed varying results. Rat patellar tendons
were injected each week, for 4 weeks, with PGE2. The tendons showed improved
biomechanical strength and stiffness at 8 weeks [31]. These results show that more
investigation into an appropriate injection model protocol is needed to ensure a more
accurate in vivo simulation of tendinopathy.
2.6.2 In vitro culture studies
Due to the difficulty controlling tendon loading in vivo, several in vitro models
have been developed to quantify tissue changes during stress deprivation, cyclic loading,
and overuse. The changes seen both biochemically and mechanically in tendon with and
without loading can be assessed in cell or tissue culture.
A basic model of the cellular mechanisms that may be implicated in tendinopathy
can be achieved by cyclically loaded cells in culture. Fibroblasts cultured on a flexible
substrate that can be subjected to stretching have shown changes in protein expression
and synthesis, as well as changes in release of various cytokines and inflammatory
molecules. Thus, these factors might be considered to have a role in the development and
modulation of injury [107-112]. However, without the extracellular matrix, tissue
properties cannot be assessed.
Tissue explant models can examine the cellular responses of tendon fibroblasts to
mechanical loads, as well as determine the effect of those responses on the extracellular
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matrix. By utilizing a tissue loading device, tendons can be exposed to stress deprivation
conditions, static loads or cyclic loads and changes in the biochemical and mechanical
properties can be measured [90, 113-116]. The main advantage of these types of systems
is that loading can be controlled, which allows for more precise determination of the
effects of loading on tendon.
Chapter 3
RESEARCH DESIGN AND METHODS
3.1 Research Design Specific Aims
AIM 1: Design and fabricate a device to allow static loading and creep
measurement of viable rat tail tendon fascicles submerged in media and housed in an
incubator.
• Hypothesis 1: System will allow for short term creep studies by being
able to statically load rat tail tendon and monitor changes via strain
analysis during loadings.
AIM 2: To evaluate the mechanical response (strain accumulation and
mechanical properties) of rat tail tendon fascicles to PGE2 exposure while under 0.3 MPa
static load and unloaded.
• Hypothesis 2.1: Tendons will require at least 24 hours of PGE2 exposure
in culture in order to display effects.
• Hypothesis 2.2: PGE2 will increase creep in culture while maintaining
failure stress levels as compared to untreated tendons.
AIM 3: Determine if MMPs have a role in the mechanical response of tendon to
PGE2 exposure.
• Hypothesis 3.1: Effects of PGE2 will be reversed by addition of a broad-
spectrum MMP inhibitor to the system.
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• Hypothesis 3.2: Effects of PGE2 will be reversed by addition of an MMP-
3 inhibitor.
3.1.1 Design and Fabrication of the Tendon Loading Apparatus
In order to statically load rat tail tendon fascicles, there were considerable design
constraints. The tendon ends must ideally be unsubmerged for gripping, while the
midsubstance is submerged in treated media. With this constraint we determined that the
tendons should be cultured in a glass Pasteur pipette, as described by Wood, et al.
containing the experimental media. However, we improved upon this method by
threading through a rubber stopper from a 7.0 ml Vacutainer tube order to have a
substantial base for static loading in culture. This stopper housed a tube prepared from a
Pasteur pipette, which was then able to store media during culture.
The end of the tendon fascicle was allowed to dry for 15 minutes and the dried
end was threaded through the eye of a straight needle. The needle with fascicle was then
inserted longitudinally through the center of the stopper. The stopper was then placed on
the glass tube and the tube filled with media. This setup ensured the midsection was
exposed to experimental media while the section for clamping was dry and isolated from
the media A drawing of the culture tube setup is illustrated in Figure 10.
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Figure 10: Schematic drawing of tube-stopper apparatus with tendon fascicle pulled through
Once the culture tubes were designed, the loading apparatus could be developed.
The design criteria identified were: easy to assemble, disassemble, sterilize, use within a
biological incubator, and house our laboratory’s preexisting calibration rods for use with
our visual strain analysis system to measure tendon lengthening in culture. The device
was machined by the UNC Physics Instrument Shop out of aluminum based on our
design (Appendix A).
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Figure 11: Incubator setup with static tissue loading device
Figure 11 shows the static loading device. It has the capability to house 12
individual tubes with stoppers as well as one calibration rod per sample. The loading bar
is placed directly above the tubes, and fish weights are draped over the rod with fishing
line until the desired stress level is achieved in the tissue.
Tendon fascicles were loaded in this apparatus by thumb screws holding the
Vacutainer tube stoppers in place with the media-containing culture tubes upright. The
end of the fascicle above the culture media was dried out as previously mentioned, and
was then affixed with Loctite super glue between two 1 cm2 silicone rubber pads. Also
affixed between these pads was the end of a fishing line that attached on the opposite end
to a small weight of approximately 14 g which was then draped over the static loading
bar to apply an approximate 0.3 MPa load to the fascicle. This load level was determined
in pilot studies that showed control tendon fascicles under 0.3 MPa load for 16 hours
acquired about a 5% strain.
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Rubber
Stopper
Thumb
Screws
Static
Loading Bar
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3.1.2 Tissue Culture Methods
Using the static loading device, experiments to measure accumulated strain were
carried out. Tissue was obtained from untreated Sprague Dawley rats sacrificed for other
uses. In order to control the variability between rat sources, only female Sprague Dawley
retired breeder rats within the weight range of 300-400 g were used in these experiments.
Tendon fascicles were isolated by removing the tail from the animal via an
incision between the two most proximal vertebrae. The opposite end of the tail was cut
between two more distal vertebrae, approximately 5 cm proximally from the distal tip.
Individual fascicles were teased from the tendons out the distal end of the tail.
Isolated fascicles were hydrated in a sterile media bath. Fascicles of similar size
were isolated and laid taut across a Petri dish. This resulted in both fascicle ends
becoming dried out, while the fascicle midsubstance remained submerged in sterile
media. Diameters were measured using an eye-piece micrometer on an Olympus Tokyo
CK inverted microscope; only tendons with cross-sectional areas of 370 ± 25 µm were
used in the study. Once fascicles were isolated and measured, they were threaded
through a glass tube and rubber stopper using a sterile straight sewing needle as described
in section 3.1.1. The tube was then filled with 1.5 ml sterile media without any
experimental additives. The tissue was allowed to equilibrate for two hours in an
incubator before this media was aspirated and replaced with experimental media.
Tissue culture medium for all groups consisted of phenol-red free DMEM-H
media (pH 7.2) supplemented with 20mM Hepes, 100IU/ml penicillin, 100µg/ml
streptomycin, 2µg/ml amphoteracin B, 100µM ascorbate, 1mM sodium pyruvate, and
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4mM L-glutamine. The final media additive was 2µM arachidonic acid, a supplement to
insure adequate substrate for the production of prostaglandins. Additionally,
experimental groups received either 1µg/ml prostaglandin E2 (Cayman Chemicals) alone,
or in combination with 5µM of a broad range MMP inhibitor (Chemicon) or 50µM
specific MMP-3 inhibitor (EMD Biosciences).
For Aim 2 experiments, the rat tail tendon fascicles were randomly divided into
two loading regimen groups: 1) loaded and 2) unloaded, and two treatment groups: 1)
control and 2) PGE2. The loaded groups underwent 24 hours of unloaded culture before
the introduction of a 0.3 MPa static tensile load for 16 hours. Load was applied after 24
hours of culture by hanging a 14 gram fish weight over the tendon-hanging bar. The
unloaded group remained unloaded for the entire 40 hour culture period and underwent
material property testing at the following timepoints: 0 hour (immediately following
harvest), 6 hour, 12 hour, 24 hour, and 40 hour. Material property testing methods will
be subsequently described. Sample sizes were as follows: Loaded, control group
contained 10 fascicles; loaded, PGE2-treated fascicles contained 8 fascicles; unloaded,
control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles contained 9
fascicles.
Two blue #6-0 sutures were used as strain markers affixed via Loctite gel super
glue at the top of the tube and on the dried tissue above solution. Strain was measured
either using a visual strain analysis system (VSA) [117] or digital microcalipers initially
after the preculture media was added, then immediately after the experimental media was
introduced, after 24 hours of unloaded culture (beginning of static load), and after 16
hours of static load. Figure 12 shows a close-up image of the tendon fascicles in the
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static loading device during culture. The initial gage length of the entire tissue was
measured, and then deformation was measured subsequent to this with a reduced field of
view containing the strain markers and calibration rods in order to increase the resolution
of the VSA system.
Figure 12: Rat tail tendons during statically loaded culture with either suture markers or ink
markers and calibration rods in order to measure strain using a camera and visual strain analysis
program
The experiments of Aim3 investigated the role of MMP activity in the tissue effects
induced by PGE2 exposure. For this Aim, tendon fascicles in all groups were cultured
unloaded for 40 hours. Experiments consisted of 4 treatment groups: 1) Control (n=15),
2) PGE2 (1µg/ml) (n=10), 3) PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM,
n=12), and 4) PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM, n=12).
After 40 hour in unloaded culture, the tendon fascicles underwent material property
testing.
Parafilm
Calibration Rods
Ink Markers
Suture
Markers
0.25”Rat Tail Tendon
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Immediately following culture, fascicles in tubes were placed in a 4ºC refrigerator
until mechanically loaded by a servo-hydraulic materials testing system (8500 Plus,
Instron Corporation, Canton, MA, USA). Before testing, the tendon was cut from the
stopper and affixed with Loctite gel super glue between two square, silicone rubber grips.
The tissue was wrapped in saline-soaked gauze until loaded into the grips of the tensile
tester. Figure 13 illustrates the failure test setup, which was conducted completely
submerged in a PBS bath at room temperature. The failure test regimen began with pre-
conditioning ten cycles of a 1% strain, 0.5 Hz haver-sine waveform prior to failure testing
with a 1% strain/sec linear ramp. Load cell (Model 31, Sensotec, Columbus, OH) and
grip strain data (maximum nonlinearity error of 0.2% of full scale +/- 75mm LVDT) were
gathered during the failure loading for structural and material property analysis.
Instron Series IX software was utilized to calculate maximum load, maximum
stress, strain at maximum load, energy at maximum load and Young’s modulus during
the failure test was calculated. The Young’s modulus calculation was made via a linear
regression between the limits of 25% and 75% of the maximum load.
42
Figure 13: Instron failure testing setup
3.1.3 Statistical Analysis
One-way analysis of variance (ANOVA) followed by Tukey’s mean comparison
testing was utilized to evaluate differences in mechanical properties between treatment
groups. Two-way ANOVA was utilized to evaluate the mechanical property changes
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caused by PGE2 treatment over time. A significance level of 0.05 was used for these
tests.
Chapter 4
RESULTS
4.1 PGE2 Timecourse
Rat tail tendon fascicles were cultured, unloaded, with or without 1 µg/ml PGE2 for
40 hours. The tissue material properties were measured in a tensile failure test
immediately (time 0), and then at 6 hours, 12 hours, 24 hours and 40 hours.
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Figure 14: Maximum stress value reached during tensile failure test of tendon fascicles cultured with
and without PGE2 unloaded for 40 hours. Error bars indicate standard deviations. Asterisks
represent significant differences between groups (2-way ANOVA, Tukey’s test for multiple
comparisons, P < 0.05). Sample sizes were as follows: Loaded, control group contained 10 fascicles;
loaded, PGE2-treated fascicles contained 8 fascicles; unloaded, control fascicles contained 10
fascicles; and unloaded, PGE2-treated fascicles contained 9 fascicles.
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The PGE2 and control groups show no significant differences in stress at failure
before the 40 hour time point. At 40 hours, the PGE2-treated tissue displayed a 23.5%
decrease in average stress level at failure as compared to control (Figure 14).
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Figure 15: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured
with and without PGE2 unloaded for 40 hours. Error bars indicate standard deviations. Asterisks
represent significant differences between groups (2-way ANOVA, Tukey’s test for multiple
comparisons, P < 0.05). Sample sizes were as follows: Loaded, control group contained 10 fascicles;
loaded, PGE2-treated fascicles contained 8 fascicles; unloaded, control fascicles contained 10
fascicles; and unloaded, PGE2-treated fascicles contained 9 fascicles.
PGE2’s effects on tendon fascicle stiffness were measured via calculation of
Young’s modulus. As with stress at failure, stiffness levels of PGE2-treated tissue did
not show a significant decrease before the 40 hour time point. At the 40 hour time point,
the average modulus of the PGE2 group was 24.5% lower than that of controls (Figure
15).
The strain to failure for both PGE2-treated and control tendon fascicles was
unchanged throughout the 40 hour culture (Figure 16). Likewise, energy measurements
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show no significant differences between PGE2 and control groups at any point during the
time course study (Figure 17).
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Figure 16: Strain measured during tensile failure tests of rat tail tendon fascicles cultured with and
without PGE2 unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as
follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated fascicles contained 8
fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles
contained 9 fascicles.
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Figure 17: Energy measured during tensile failure tests of rat tail tendon fascicles cultured with and
without PGE2 unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were as
follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated fascicles contained 8
fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles
contained 9 fascicles.
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4.2 Statically Loaded Tendon
After characterization of PGE2’s effects in rat tail tendon fascicles over the
culture time period, the tendons were then exposed to static load in culture. All fascicles
were cultured, unloaded, with or without 1µg/ml PGE2 for 24 hours, and then were
loaded with an approximate 0.3 MPa load for 16 hours. Tissue lengths were measured
for strain calculation at four time points: 1) initially after harvest, 2) after experimental
media addition, 3) after 24 hours at the beginning of static load application, and 4) after
16 hour static load.
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Figure 18: Strain measured before and after 0.3 MPa static load applied in culture to rat tail tendon
fascicles treated with or without PGE2 and unloaded for 24 hours followed by 16 hour static load.
Error bars indicate standard deviation. 4-point stars represent significant difference from own first
strain measurement, and 5-point stars represent significant differences from control at that same
time point (2-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05). Sample sizes were as
follows: Loaded, control group contained 10 fascicles; loaded, PGE2-treated fascicles contained 8
fascicles; unloaded, control fascicles contained 10 fascicles; and unloaded, PGE2-treated fascicles
contained 9 fascicles.
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No strain accumulation differences were observed between control and PGE2 groups
during initial preculture before experimental media was introduced. During the 24 hour
unloaded culture, the PGE2-treated fascicles accumulated a negative strain which is
significantly different from the positive strain accumulation seen in the control group at
the same time point (Figure 18). After the 16 hour static load, PGE2-treated and control
tendons show no difference in the amount of strain accumulated (Figure 18). The
significant differences seen in mechanical properties of failure stress and Young’s
Modulus between the PGE2 and control tendons after 40 hours in unloaded culture were
eliminated with the introduction of a 16 hour static load (Figure 19 and 20). Failure
strain and energy to failure were not significantly effected by either treatment or loading
regimen (Figures 21 and 22).
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Figure 19: Maximum stress value reached during tensile failure test of rat tail tendon fascicles
cultured with and without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded
for 24 hours followed by 16 hour 0.3 MPa static load in culture. Error bars indicate standard
deviation. Asterisks represent significant differences between groups (1-way ANOVA, Tukey’s test
for multiple comparisons, P < 0.05). Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml)
(n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus
specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12).
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Figure 20: Young’s Modulus measured during tensile failure test of rat tail tendon fascicles cultured
with and without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24
hours followed by 16 hour 0.3 MPa static load in culture. Error bars indicate standard deviation.
Asterisks represent significant differences between groups (1-way ANOVA, Tukey’s test for multiple
comparisons, P < 0.05). Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2
(1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12).
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Figure 21: Strain measured during tensile failure test of rat tail tendon fascicles cultured with and
without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24 hours
followed by 16 hour 0.3 MPa static load in culture. Error bars indicate standard deviation. Sample
sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP
inhibitor (bMMPi, 5µM) (n=12).
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Figure 22: Energy measured during tensile failure test of rat tail tendon fascicles cultured with and
without PGE2 (1µg/ml) and either unloaded for 40 hour culture time, or unloaded for 24 hours
followed by 16 hour 0.3 MPa static load in culture. Error bars indicate standard deviation. Sample
sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP
inhibitor (bMMPi, 5µM) (n=12).
4.3 Nonspecific MMP inhibition
A broad-spectrum MMP inhibitor was introduced to the unloaded culture system
in order to determine MMPs role in PGE2-induced changes in mechanical properties.
When PGE2-treated fascicles were also cultured with the MMP inhibitor, their failure
stress levels were no different from controls after 40 hours. The tendons treated with
PGE2 alone displayed a significant decrease in failure stress levels when compared to
both control groups and the group treated with PGE2 plus MMP inhibitor (Figure 23).
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Figure 23: Maximum stress value reached during tensile failure test of rat tail tendon fascicles
cultured with and without PGE2 (1µg/ml) and with or without 5 µM of a broad-spectrum MMP
inhibitor unloaded for 40 hours. Error bars indicate standard deviation. Asterisks represent
significant differences between groups (1-way ANOVA, Tukey’s test for multiple comparisons, P <
0.05). Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus
broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor
(sMMP3i, 50 µM) (n=12).
The MMP-inhibitors effects on tissue stiffness after a 40 hour unloaded culture
were similar to the effects on failure stress. Tendon tissue treated with PGE2 alone
showed a significant decrease in stiffness as compared with the control group or the
PGE2 plus inhibitor group (Figure 24). The MMP inhibitor caused the tissue stiffness in
the PGE2-treated group to remain at the same level as controls.
The broad-spectrum MMP inhibitor did not have any significant effect on the
strain to failure during the tensile failure test in any group (Figure 25). However, the
inhibitor’s effects on energy density was similar to its effects on failure stress and
Young’s modulus, in that the inhibitor maintained energy levels similar to controls, while
PGE2 caused a significant decrease in energy during the tensile failure test (Figure 26).
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Figure 24: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured
with or without PGE2 (1µg/ml) and with or without 5 µM of a broad-spectrum MMP inhibitor
unloaded for 40 hours. Error bars indicate standard deviation. Asterisks represent significant
differences between groups (1-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05).
Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad
MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i,
50 µM) (n=12).
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Figure 25: Strain measured during tensile failure test of rat tail tendon fascicles cultured with or
without PGE2 and with or without a broad spectrum MMP inhibitor (5µM) unloaded for 40 hours.
Error bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2
(1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2
(1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12).
Figure 26: Energy measured during tensile failure test of rat tail tendon fascicles cultured with or
without PGE2 (1µg/ml) and with or without 5 µM of a broad-spectrum MMP inhibitor unloaded for
40 hours. Error bars indicate standard deviation. Asterisks represent significant differences
between groups (1-way ANOVA, Tukey’s test for multiple comparisons, P < 0.05). Sample sizes were
as follows: Control (n=15), PGE2 (1µg/ml) (n=10), PGE2 (1µg/ml) plus broad MMP inhibitor
(bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12).
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4.4 Specific MMP-3 Inhibition
Rat tail tendon fascicles were cultured with or without 1 µg/ml PGE2, and those
cultured with PGE2 were also cultured with or without 50 µM of a specific MMP-3
inhibitor, for 40 hours in unloaded culture. Immediately following culture, the tissue was
loaded to failure in a tensile failure test to obtain strength, strain, stiffness and energy
measurements.
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Figure 27: Maximum stress value reached during tensile failure test of rat tail tendon fascicles
cultured without PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the
specific MMP-3 inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard deviation.
Sample sizes were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus
specific MMP-3 inhibitor (sMMP3i, 50 µM) (n=12).
No significant differences were found in the stress measured at failure between
the groups (Figure 27). However, there was a trend for PGE2 to decrease the stress seen
at failure and for the specific MMP-3 inhibitor to increase the stress in the tendon at
failure. Tendon stiffness was unaffected by any of the treatment groups (Figure 28). The
specific MMP-3 inhibitor tended to increase the strain to failure and energy over control
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and PGE2-treated tendons, though these increases were not significantly different
(Figures 29 and 30).
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Figure 28: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-
3 inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes
were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).
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Figure 29: Maximum strain measured during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-
3 inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes
were as follows: Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).
58
Specific MMP-3 Inhibitor Effects on Energy
0
2
4
6
8
10
12
Control PGE2 PGE2 +Specific MMP-3
InhibitorTreatment
m
J
Figure 30: Energy measured during tensile failure test of rat tail tendon fascicles cultured without
PGE2 (1µg/ml) or inhibitor (Control), with PGE2 only, or with PGE2 and the specific MMP-3
inhibitor (50 µM) unloaded for 40 hours. Error bars indicate standard deviation. Sample sizes were
as follows: Control (n=15), PGE2 (1µg/ml) (n=10), and PGE2 (1µg/ml) plus specific MMP-3 inhibitor
(sMMP3i, 50 µM) (n=12).
The effects of the broad-spectrum MMP inhibitor (Ilomastat) and the specific
MMP-3 inhibitor were compared by culturing rat tail tendon fascicles with PGE2 at a
concentration of 1 µg/ml and the broad inhibitor at a concentration of 5 µM and the
specific inhibitor at a concentration of 50 µM.
A non-significant increase was detected in the stress at failure and energy of the
groups treated with the specific MMP-3 inhibitor over the broad-spectrum MMP inhibitor
(Figure 31 and 34). The stiffness of tissue cultured with the specific MMP-3 inhibitor
showed a slight increase over the stiffness of those cultured with the broad-spectrum
MMP inhibitor, but the change was not statistically significant (Figure 32). The strains at
failure showed no significant difference between the groups (Figure 33).
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Figure 31: Maximum stress value reached during tensile failure test of rat tail tendon fascicles
cultured without PGE2 (1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP
inhibitor (Ilomastat, 5 µM), or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40
hours. Error bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2
(1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).
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Figure 32: Young’s modulus measured during tensile failure test of rat tail tendon fascicles cultured
without PGE2 (1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor
(Ilomastat, 5 µM), or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours.
Error bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2
(1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).
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Figure 33: Strain measured during tensile failure test of rat tail tendon fascicles cultured without
PGE2 (1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor
(Ilomastat, 5 µM), or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours.
Error bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2
(1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).
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Figure 34: Energy measured during tensile failure test of rat tail tendon fascicles cultured without
PGE2 (1µg/ml) or inhibitor of any kind (Control), with PGE2 and the Broad MMP inhibitor
(Ilomastat, 5 µM), or with PGE2 and the specific MMP-3 inhibitor (50 µM) unloaded for 40 hours.
Error bars indicate standard deviation. Sample sizes were as follows: Control (n=15), PGE2
(1µg/ml) plus broad MMP inhibitor (bMMPi, 5µM) (n=12), and PGE2 (1µg/ml) plus specific MMP-3
inhibitor (sMMP3i, 50 µM) (n=12).
Chapter 5
DISCUSSION
PGE2 has long been implicated as a precursor to tendinopathy development.
During tendon loading there are increases in both PGE2 levels and MMP levels in tendon
[18, 35, 85, 86]. MMPs have been increasingly investigated for their role in tendinopathy
development, yet the correlation between PGE2 levels and specific MMP synthesis and
activity has only recently begun to be explored [118].
The cause of tendinopathy has been classically described as an overuse
phenomenon, resulting from an accumulation of fiber ‘micro-injuries’. The exact
molecular mechanisms are unknown, but it has been suggested that the local strain loss
due to these fiber failures initiates a catabolic response in the tenocytes associated with
that fibril [24]. This may include an increase in metalloproteinase activity similar to the
mechanisms seen in load-deprived tendon [37, 113, 119].
PGE2 has been shown to decrease collagen type I production as well as increase
MMP-1 and 3 expression and synthesis in cultured tendon fibroblasts [73, 118]. The in
vitro system used in our study has been developed to study the effects of PGE2 on rat tail
tendon fascicles during unloaded and loaded culture. PGE2 was shown to decrease the
mechanical properties of the tissue after 40 hours in unloaded culture, and to illicit no
change in response after loaded culture. This is consistent with an increase in MMP, as it
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has been shown that MMP expression is inhibited in statically loaded rat tail tendon in
vitro [37] and collagenase is unable to cleave tendon in tension [119].
The strain measurements made during the loaded culture showed a significant
contraction of the tendons treated with PGE2 after the initial 24 hour unloaded culture. It
has been well documented that certain fibroblasts can assume a contractile phenotype in
vitro which may account for this shortening [120]. However, it is interesting that PGE2
appears to be the cause of this contraction, as the process has also been shown to depend
on increased MMP activity [121]. It has been shown previously that the Ilomastat MMP-
inhibitor used in this study will limit contraction of a fibroblast-populated type I collagen
lattice and rat tail tendon contraction in culture [121, 122]. This further suggests PGE2’s
actions are due to an increase in MMP activity in the culture system.
To help determine if MMP activity was responsible for the changes observed in
the PGE2-treated tendon, we utilized a broad-spectrum MMP inhibitor. The inhibitor,
Ilomastat, was chosen because it had been previously used in a rat tail tendon culture
system to inhibit MMP-13, specifically, and is known to inhibit most MMPs [122, 123].
Ilomastat eliminated the decreases in material properties caused by exogenous PGE2 in
the 40 hour unloaded culture system. These findings suggest that PGE2 acts to reduce
material properties in the rat tail tendon after 40 hours of unloaded culture through an
increase in MMP activity.
It has been shown that the cytokine IL-1 may act on tendon through an increase
in PGE2 coupled with an increase in the EP4 receptor. This then amplifies the cellular
response to PGE2, which results in increased expression of MMP-1 and MMP-3 [81].
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Early increases in collagenase are thought to potentially contribute to tendinopathy
development over time, but the role of MMP-3 is not well understood.
PGE2 is applied clinically to induce cervical remodeling and softening seen
during labor. As in tendon, PGE2 in the cervix has been shown to effect cervical tensile
strength and collagen organization via the EP4 receptor [82, 99]. However, the effect of
PGE2 on MMP-3 expression, synthesis and activity has been explored in more depth in
the cervix. It has been found that MMP-3 expression parallels cervical tensile strength
changes during pregnancy more closely than collagenase [77] MMP-3 is a potent
activator of MMP-1, as well as many of the other MMPs, and its increased activity level
in PGE2-treated tendon may be the instigator of degeneration. MMP-3’s ability to cleave
extracellular glycoproteins may also affect intrafibrillar interactions and alter tendon
mechanical properties without cleaving collagen I [36]. In order to investigate the role
of MMP-3 in tendon, we employed a specific inhibitor of MMP-3 in our tissue culture
system.
The failure properties of rat tail tendon fascicles cultured with PGE2 and a
specific MMP-3 inhibitor did not display a significant difference, though there was a
trend for the fascicles treated with the MMP-3 inhibitor to have increased mechanical
properties. The PGE2-treated tendon tissue showed less drastic decreases in properties in
these groups than had been seen in our earlier work. We have proposed that these
discrepancies may be due to differences between the PGE2 itself or the different animals’
sensitivity to its effects. The broad-spectrum inhibitor has been used in a rat tail model
previously, but was only validated to reduce MMP-13 (equivalent to human MMP-1) in
that model [122]. This data shows a slight indication that MMP-3 has the potential to be
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an important mediator of tendon degeneration, as it maintained the mechanical properties
better than any other treatment group after 40 hours of unloaded culture. The inability to
detect significant changes in many of these properties may be due to the small sample
size for these experiments.
There are many limitations involved in the experiments presented here, mainly
stemming from the use of multiple rat populations. During our screening for rats, we
attempted to normalize as many factors as possible in order to reduce variability. This
included exclusively harvesting tails from female Sprague-Dawley retired breeder rats in
the weight range of 300-400g. However, we did not limit the animals to a specific age
range which has been shown to have significant effects on rat tail tendon mechanical
properties [124]. Also, rats utilized for the PGE2 time course experiments, the static
loading experiments, and the broad-spectrum Ilomastat MMP inhibitor experiments
utilized rats from a single population, whereas the specific MMP-3 inhibitor experiments
were completed with rats from another population. This would have introduced genetic
variability that may account for the differential effects of PGE2 on these tissue
mechanical properties.
In order to further decrease variability between fascicles, the tissue could be
harvested from a specific tendon location in the rat tail, either dorsal or ventral. Tendons
in the same tail region would experience similar loads in vivo, and would thus have less
mechanical property variation. Likewise, ensuring a random distribution of tendons from
any given animal amongst treatment groups would decrease variability. In the studies
presented here, the fascicles were isolated from each animal and combined in sterile
media in a Petri dish. This accounted for randomizing fascicles from different animal
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sources and different tendon locations within the tails, but could be improved in future
work.
To combat the issues seen in these studies with variable effects of PGE2on tendon
fascicles isolated from different rat populations, a dose response of fascicles to PGE2
could be completed. This would determine an ideal PGE2 concentration that would elicit
a response in a broader assortment of rat populations.
Other limitations in these experiments are due to the lack of biochemical and
histological analysis. In order to develop a more complete picture of PGE2’s effects in
tendon, biochemical analysis of collagen and glycosaminoglycan levels could be
determined. Moreover, in order to definitively determine enzyme activity in tendon due
to PGE2 specific MMP-1 and MMP-3 assays could be employed. Using histology could
also allow for a more precise determination of extracellular matrix changes due to PGE2
and MMP action.
In conclusion, PGE2’s degeneration of tendon mechanical properties appears to be
carried out via the action of MMPs. However, the key to treating tendon degradation
disorders may be in determining the specific MMP responsible for these changes. The
role of MMP-3 in tendon should be explored further, as inhibition of this enzyme
increases the stress to failure and energy in tendon significantly over inhibition of
collagenase. Isolating the early contributors to tendinopathy development may better
direct future pharmaceutical treatments, and further help preventative measures.
Other future work can include an investigation of different loading regimens.
This work explored static tensile loading, however a more physiologic loading protocol
would involve cyclic loading of the tendon. The static loading device presented here
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could be modified to accommodate a change in loading regimen, with either the tendon
hanging bar cyclically moved up and down, or the base housing the culture tubes may
oscillate to strain the tendons.
The work presented here attempts to investigate the relationship between PGE2,
collagenase, and MMP-3. While there are several limitations in this research, it does
provide a beginning look at MMPs and MMP inhibition with PGE2 exposure in tendon.
In the future, these studies can be used as an initial basis for development of more
loading regimes and treatments in order to further increase the understanding of PGE2’s
effects in tendons and tendinopathy.
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Appendix 1: Static Loading Device Drawings
Figure 35: Tendon hanging rod for statically loading tendon in incubator
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Figure 36: Stopper holder device for incubator
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Figure 37: Calibration rods for visual strain analysis
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Figure 38: Stopper holder device assembled with calibration rods
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Appendix 2: Prostaglandin E2 Concentration Calculation
The PGE2 concentration of 1 µg/ml used in the culture system was primarily
based on PGE2 levels seen previously in a cyclic loading tissue culture system in our
laboratory. PGE2 levels in culture medium were measured after 12 days of 4 hour per
day cycles of a 12 MPa load. This system utilized chicken digital flexor tendons, which
were found to produce approximately 70,000 pg/ml PGE2 [125]. The vast difference in
cross-sectional area between the digital flexor tendon and rat tail tendon (3 mm2 for
chicken tendon as compared with ~0.1 mm2 for rat tail tendon), as well as the much
higher media volume (37.5 ml media in chicken experiments compared with 1.5 ml
media for rat tail experiments), were used to scale the concentration for the current
system and ensure the final concentration is considered relatively stable [126]. PGE2 was
obtained from Cayman Chemicals (Dinoprostone, Catalog #14010) as 1 mg of solid. The
calculations of amount per milliliter of media are outlined below.
Prostaglandin E2; Dinoprostone (CAS 363-24-6)
Arrives: 1 mg Working Concentration: 1 µg/ml
Molecular Weight: 352.5
Reconstitute PGE2 in 1 ml 100% ethanol: [PGE2]vial = 1 mg/ml
Experimental Media Volume = 1.5 ml
From Chicken tendon study:
• 12 MPa Load-induced [PGE2] = 70,000 pg/ml
• Chicken tendon volume = ~120 µL
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• 70,000 pg/ml PGE2 x 37.5 ml media = 2.59 µg PGE2
Rat tail tendon volume (assuming 300µm diameter and 70 mm length) = ~10µL
Scale PGE2 amount: 2.59 µg PGE2 (10µL rat tail/120 µL chicken) = 0.216 µg PGE2
Want approximately 0.216 µg PGE2 in 1.5 ml media: 0.144 µg/ml
Choose 1 µg/ml PGE2
[PGE2]vial = 1000 µg/ml, need 1:1000 dilution
***1 µL PGE2 per 1 ml media***
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Appendix 3: Inhibitor Concentration Calculations
Appendix 3.1
Broad-spectrum MMP Inhibitor (Ilomastat, GM6001) Concentration
The broad-spectrum MMP inhibitor, Ilomastat, used in our rat tail tendon model
was determined from previous studies in which it proved effective [122, 127]. The
inhibitor was obtained from Chemicon International (GM6001 [Ilomastat] MMP
Inhibitor, Catalog # CC1000). It arrived in a concentration of 1 mg/ml (2.5 mM) in
DMSO. The calculations for determining the amount per milliliter of media outlined
below.
GM6001 [Ilomastat] MMP Inhibitor
Arrives: 1 mg/ml = 2.5 mM Working Concentration: 5 µM
2.5 mM = 2.5 x 103 µM
2500 µM / 5 µM = 500 X
(Must be diluted by a factor of 500)
2 µL stock ilomastat per 1 ml media = [Ilomastat] of 5 µM
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Appendix 3.2 
Specific MMP-3 Inhibitor Concentration
The chemical name for the specific MMP-3 inhibitor is 4-(4’-Biphenyl)-4-
hydroxyimino-butyric acid. It was obtained from Calbiochem (MMP-3 Inhibitor VI,
Catalog #444265) as 5 mg of a white solid. The concentration used in our culture system
was determined from the Ki values found both in vivo and in vitro [128, 129]. We
determined that a 50 µM concentration of this inhibitor would be effective to block
MMP-3 activity. The calculations for determining the amount per milliliter of media
outlined below.
MMP-3 Inhibitor VI
Arrives: 5 mg Working Concentration: 50 µM
Molecular Weight: 269.3
Solubility: DMSO
Determine moles of inhibitor: 0.005g / 269.3 = 18.56 µmol
Reconstitute with 1 ml DMSO: Inhibitor concentration = 0.0186 M ~ 0.02 M
0.02 M / 50 µM = 400 X
(Must be diluted by a factor of 400)
1 µL stock MMP-3 inhibitor per 400 µL media = [MMP-3 Inhibitor] of 50 µM
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